Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.

Smith V, Herrick AL, Ingegnoli F, Damjanov N, Angelis, Denton CP, Distler O, Espejo K, Foeldvari I, Frech T, Garro B, Gutierrez M, Gyger G, Hachulla E, Hesselstrand R, Iagnocco A, Kayser C, Melsens K, Müller-Ladner U, Pizzorni C, Radic M, Riccieri V, Snow M, Stevens W, Sulli A, van Laar JM, Vonk MC, Vanhaecke A, Cutolo M; EULAR Study Group on Microcirculation in Rheumatic Diseases and the Scleroderma Clinical Trials Consortium Group on Capillaroscopy.

Autoimmun Rev. 2020 Jan 9:102458. doi: 10.1016/j.autrev.2020.102458. [Epub ahead of print] Review.

2.

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG.

Rheumatology (Oxford). 2019 Dec 20. pii: kez602. doi: 10.1093/rheumatology/kez602. [Epub ahead of print]

PMID:
31859346
3.

Cardiovascular risk in patients with new gout: should we reclassify the risk?

Gamala M, Jacobs JWG, Linn-Rasker SP, Nix M, Heggelman BGF, Pasker-de Jong PCM, van Laar JM, Klaasen R.

Clin Exp Rheumatol. 2019 Nov 20. [Epub ahead of print]

PMID:
31820724
4.

Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective.

Spierings J, van Rhijn-Brouwer FCC, de Bresser CJM, Mosterman PTM, Pieterse AH, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Kars MC, van Laar JM.

Rheumatology (Oxford). 2019 Dec 6. pii: kez579. doi: 10.1093/rheumatology/kez579. [Epub ahead of print]

PMID:
31808528
5.

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041. eCollection 2019.

6.

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, van Assen S, Elkayam O.

RMD Open. 2019 Sep 9;5(2):e001035. doi: 10.1136/rmdopen-2019-001035. eCollection 2019.

7.

How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?

Spierings J, van den Ende CHM, Schriemer RM, Moens HJB, van der Bijl EA, Bonte-Mineur F, de Buck MPD, de Kanter MAE, Knaapen-Hans HKA, van Laar JM, Mulder UDJ, Potjewijd J, de Pundert LAJ, Schoonbrood THM, Schouffoer AA, Stel AJ, Vercoutere W, Voskuyl AE, de Vries-Bouwstra JK, Vonk MC.

Rheumatology (Oxford). 2019 Sep 20. pii: kez417. doi: 10.1093/rheumatology/kez417. [Epub ahead of print]

PMID:
31539063
8.

Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".

Smith V, Vanhaecke A, Herrick AL, Distler O, Guerra MG, Denton CP, Deschepper E, Foeldvari I, Gutierrez M, Hachulla E, Ingegnoli F, Kubo S, Müller-Ladner U, Riccieri V, Sulli A, van Laar JM, Vonk MC, Walker UA, Cutolo M; EULAR Study Group on Microcirculation in Rheumatic Diseases.

Autoimmun Rev. 2019 Nov;18(11):102394. doi: 10.1016/j.autrev.2019.102394. Epub 2019 Sep 11.

9.

The performance of dual-energy CT in the classification criteria of gout: a prospective study in subjects with unclassified arthritis.

Gamala M, Jacobs JWG, Linn-Rasker SF, Nix M, Heggelman BGF, Pasker-de Jong PCM, van Laar JM, Klaasen R.

Rheumatology (Oxford). 2019 Sep 5. pii: kez391. doi: 10.1093/rheumatology/kez391. [Epub ahead of print]

PMID:
31504985
10.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.

PMID:
31413005
11.

Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?

Spierings J, van Laar JM.

Rheum Dis Clin North Am. 2019 Aug;45(3):399-416. doi: 10.1016/j.rdc.2019.04.003. Epub 2019 May 27. Review.

PMID:
31277752
12.

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.

Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM.

Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13.

PMID:
31196844
13.

The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis.

Gamala M, Jacobs JWG, van Laar JM.

Rheumatology (Oxford). 2019 Dec 1;58(12):2117-2121. doi: 10.1093/rheumatology/kez180.

PMID:
31089688
14.

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review.

Verhoeven MMA, Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG.

Curr Rheumatol Rep. 2019 Apr 23;21(6):24. doi: 10.1007/s11926-019-0821-1. Review.

15.

Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.

Besselink NJ, Westgeest AAA, Klaasen R, Gamala M, van Woerkom JM, Tekstra J, Verhoeven MMA, Van Spil WE, Lafeber FPJG, Marijnissen ACA, Van Laar JM, Jacobs JWG.

Trials. 2019 Apr 17;20(1):226. doi: 10.1186/s13063-019-3285-8.

16.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, Bijlsma JWJ, Jacobs JWG.

Joint Bone Spine. 2020 Jan;87(1):13-23. doi: 10.1016/j.jbspin.2019.04.002. Epub 2019 Apr 11.

PMID:
30981868
17.

Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis.

van Eden W, Jansen MAA, Ludwig IS, Leufkens P, van der Goes MC, van Laar JM, Broere F.

Front Immunol. 2019 Feb 22;10:279. doi: 10.3389/fimmu.2019.00279. eCollection 2019. Review.

18.

Automated CT quantification methods for the assessment of interstitial lung disease in collagen vascular diseases: A systematic review.

van Royen FS, Moll SA, van Laar JM, van Montfrans JM, de Jong PA, Mohamed Hoesein FAA.

Eur J Radiol. 2019 Mar;112:200-206. doi: 10.1016/j.ejrad.2019.01.024. Epub 2019 Jan 24.

PMID:
30777211
19.

Second autologous haematopoietic stem cell transplantation in systemic sclerosis-a case report.

van Rhijn-Brouwer FCC, Spierings J, van Rhenen A, Kuball J, van Laar JM.

Rheumatology (Oxford). 2019 Jul 1;58(7):1305-1307. doi: 10.1093/rheumatology/kez010. No abstract available.

20.

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.

Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber FPJG, Hwang CC, Liu X, Sasso EH, van Laar JM.

Arthritis Res Ther. 2018 Nov 20;20(1):256. doi: 10.1186/s13075-018-1750-5.

21.

Sjögren's syndrome: state of the art on clinical practice guidelines.

Romão VC, Talarico R, Scirè CA, Vieira A, Alexander T, Baldini C, Gottenberg JE, Gruner H, Hachulla E, Mouthon L, Orlandi M, Pamfil C, Pineton de Chambrun M, Taglietti M, Toplak N, van Daele P, van Laar JM, Bombardieri S, Schneider M, Smith V, Cutolo M, Mosca M, Mariette X.

RMD Open. 2018 Oct 18;4(Suppl 1):e000789. doi: 10.1136/rmdopen-2018-000789. eCollection 2018.

22.

Antiphospholipid syndrome: state of the art on clinical practice guidelines.

Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A.

RMD Open. 2018 Oct 18;4(Suppl 1):e000785. doi: 10.1136/rmdopen-2018-000785. eCollection 2018.

23.

Systemic sclerosis: state of the art on clinical practice guidelines.

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M.

RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

24.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

25.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
26.

Targeting the TLR4-MD2 axis in systemic sclerosis.

O'Reilly S, van Laar JM.

Nat Rev Rheumatol. 2018 Oct;14(10):564-566. doi: 10.1038/s41584-018-0077-6. No abstract available.

PMID:
30181583
27.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
28.

A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol.

van Rhijn-Brouwer FCC, Gremmels H, Fledderus JO, Schuurman AH, Bonte-Mineur F, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Coert JH, Radstake TRDJ, van Laar JM, Verhaar MC; MANUS Study Group.

BMJ Open. 2018 Aug 20;8(8):e020479. doi: 10.1136/bmjopen-2017-020479.

29.

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study.

Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM.

PLoS One. 2018 Aug 6;13(8):e0201527. doi: 10.1371/journal.pone.0201527. eCollection 2018.

30.

Hematopoietic stem-cell transplantation in systemic sclerosis: an update.

Spierings J, van Rhijn-Brouwer FCC, van Laar JM.

Curr Opin Rheumatol. 2018 Nov;30(6):541-547. doi: 10.1097/BOR.0000000000000541. Review.

PMID:
30063470
31.

Differential MicroRNA Expression Levels in Cutaneous Acute Graft-Versus-Host Disease.

Atarod S, Norden J, Bibby LA, Janin A, Ratajczak P, Lendrem C, Pearce KF, Wang XN, O'Reilly S, Van Laar JM, Collin M, Dickinson AM, Crossland RE.

Front Immunol. 2018 Jul 10;9:1485. doi: 10.3389/fimmu.2018.01485. eCollection 2018.

32.

RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers.

Cuppen BVJ, Rossato M, Fritsch-Stork RDE, Concepcion AN, Linn-Rasker SP, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Radstake TR; all SRU investigators.

Expert Rev Clin Immunol. 2018 Jul;14(7):623-633. doi: 10.1080/1744666X.2018.1480937. Epub 2018 Jun 6.

PMID:
29808722
33.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
34.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

35.

Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update.

Lutter L, Spierings J, van Rhijn-Brouwer FCC, van Laar JM, van Wijk F.

Front Immunol. 2018 Apr 20;9:767. doi: 10.3389/fimmu.2018.00767. eCollection 2018. Review.

36.

Optical spectral transmission to assess inflammation in hand and wrist joints of rheumatoid arthritis patients.

Besselink NJ, van der Meijde P, Rensen WHJ, Meijer PBL, Marijnissen ACA, van Laar JM, Lafeber FPJG, Jacobs JWG.

Rheumatology (Oxford). 2018 May 1;57(5):865-872. doi: 10.1093/rheumatology/kex531.

PMID:
29471516
37.

Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births.

Kroese SJ, de Hair MJH, Limper M, Lely AT, van Laar JM, Derksen RHWM, Fritsch-Stork RDE.

J Immunol Res. 2017;2017:2810202. doi: 10.1155/2017/2810202. Epub 2017 Dec 17.

38.

Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.

Gamala M, Linn-Rasker SP, Nix M, Heggelman BGF, van Laar JM, Pasker-de Jong PCM, Jacobs JWG, Klaasen R.

Clin Rheumatol. 2018 Jul;37(7):1879-1884. doi: 10.1007/s10067-018-3980-y. Epub 2018 Jan 27.

39.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

40.

Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review.

Safy M, de Hair MJH, Jacobs JWG, Buttgereit F, Kraan MC, van Laar JM.

PLoS One. 2017 Dec 21;12(12):e0188810. doi: 10.1371/journal.pone.0188810. eCollection 2017. Review.

41.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.

Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL.

Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.

42.

Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?

van Rhijn-Brouwer FCC, Spierings J, van Laar JM.

Immunol Lett. 2018 Mar;195:88-96. doi: 10.1016/j.imlet.2017.11.005. Epub 2017 Nov 16. Review.

PMID:
29155233
43.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
44.

Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study.

Kroese SJ, Abheiden CNH, Blomjous BS, van Laar JM, Derksen RWHM, Bultink IEM, Voskuyl AE, Lely AT, de Boer MA, de Vries JIP, Fritsch-Stork RDE.

J Immunol Res. 2017;2017:8245879. doi: 10.1155/2017/8245879. Epub 2017 Sep 28.

45.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

46.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

47.

Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need.

de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM.

Rheumatology (Oxford). 2017 Oct 4. doi: 10.1093/rheumatology/kex349. [Epub ahead of print]

PMID:
29029308
48.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
49.

Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al.

Safy M, Jacobs JWG, Ijff ND, Bijlsma JWJ, van Laar JM, de Hair MJH; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2018 Aug;77(8):e48. doi: 10.1136/annrheumdis-2017-212380. Epub 2017 Oct 9. No abstract available.

PMID:
28993345
50.

Targeting of tolerogenic dendritic cells towards heat-shock proteins: a novel therapeutic strategy for autoimmune diseases?

Jansen MAA, Spiering R, Broere F, van Laar JM, Isaacs JD, van Eden W, Hilkens CMU.

Immunology. 2018 Jan;153(1):51-59. doi: 10.1111/imm.12811. Epub 2017 Sep 18. Review.

Supplemental Content

Loading ...
Support Center